ESR1 and breast carcinoma: Previously, MDM2 amplification has been reported to relate to estrogen receptor status and its presence has been indicated in human breast cancer cell (Quesnel et al., 1994); was observed to be manipulated with diosgenin in the third cluster of the PPI binding (binding energy −8.5 kcal/mol).